🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07098325
Recruiting Not applicable

Biological Reaction of Direct 3d Printed Retainers

NCT07098325 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2025-10-01
Last updated
2025-08-01

Condition(s) studied

Orthodontic Retainers

Investigational drug(s) / intervention(s)

retainer with .5 mm thicknessretainer with 1 mm thickness

retainer with .5 mm thickness: direct 3d printed retainer with .5 mm thickness

retainer with 1 mm thickness: direct 3d printed retainer with 1 mm thickness,

Study summary

The aim of this study will be to evaluate the biological reaction of direct three dimensional printed retainers.

Primary objective is to evaluate bacterial growth and color stability between different thicknesses of 3d printed material used as a retainer .

Secondary objective is to determine the optimal thickness for use in clear aligner fabrication based on biological performance.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * -Finished fixed orthodontic therapy and seeking for retention as a part of their original treatment plan. * Good oral hygiene. * No habits (e.g., smoking) Exclusion Criteria: * Medication affecting saliva. * intrinsic tooth discoloration. * Uncooperative patients. * Patient with periodontitis. * Learning difficulties and inability to read written instructions.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dental Medicine , Al-Azhar University Asyut Egypt Recruiting

More Al-Azhar University trials in Egypt

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07098325 on ClinicalTrials.gov ↗ ← All trials in Egypt